SCHEDULE 13G/A 0001948604 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 12/31/2025 0001999480 Alto Neuroscience, Inc. 02157Q109 650 Castro Street Suite 450 Mountain View CA 94041 Rule 13d-1(c) K2 HealthVentures Equity Trust LLC DE 0 788995 0 788995 788995 N 2.4 OO Parag Shah X1 0 788995 0 788995 788995 N 2.4 IN HC Anup Arora X1 0 788995 0 788995 788995 N 2.4 IN HC Alto Neuroscience, Inc. 650 Castro Street, Suite 450, Mountain View, California, 94041 This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. K2 HealthVentures Equity Trust LLC ("K2HV Equity"); ii. Parag Shah ("Mr. Shah"); and iii. Anup Arora ("Mr. Arora"). This Statement on Schedule 13G relates to 30,000 shares of Common Stock held directly by K2HV Equity and 758,995 shares of Common Stock K2HV Equity has the right to acquire within 60 days, including (i) warrants to purchase 35,773 shares of Common Stock at an exercise price of $3.7122 per share, which warrants expire on December 15, 2032 (the "Original Warrants"); (ii) warrants to purchase 134,691 shares of Common Stock at an exercise price of $3.7122 per share, which warrants expire on January 13, 2035 (the "Refinance Warrants" and, together with the Original Warrants, the "Warrants"); and (iii) an aggregate 588,531 shares of Common Stock issuable to the Reporting Persons upon conversion of the remaining balance of the Issuer's outstanding debt obligations to K2HV Equity under the Loan and Security Agreement, dated as of December 16, 2022, between the Issuer and K2HV Equity, as amended by the First Amendment to Loan and Security Agreement, dated as of January 13, 2025, including 381,315 shares of Common Stock that are issuable at a conversion price of $10.49 per share (the "Original Conversion Shares") and 207,216 shares of Common Stock that are issuable at a conversion price of $4.8259 per share (the "Refinance Conversion Shares" and, together with the Original Conversion Shares, the "Conversion Shares"). K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it holds directly and has the right to acquire upon exercise of the Warrants and conversion of the Conversion Shares, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns. The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116. K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America. Y As of December 31, 2025, each of the Reporting Persons may be deemed the beneficial owner of 788,995 shares of Common Stock. This amount consists of (i) 30,000 shares of Common Stock directly held by K2HV Equity, (ii) an aggregate 170,464 shares of Common Stock K2HV Equity has the right to acquire upon exercise of the Warrants, and (iii) an aggregate 588,531 shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares. As of December 31, 2025, each of the Reporting Persons may be deemed the beneficial owner of approximately 2.4% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on the sum of (i) 31,066,335 shares of Common Stock outstanding as of November 7, 2025, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2025, (ii) 828,860 shares of Common Stock that became outstanding following K2HV Equity's conversion of Refinance Conversion Shares on November 20, 2025, (iii) an aggregate 170,464 shares of Common Stock that are issuable to K2HV Equity within 60 days upon exercise of the Warrants, and (iv) an aggregate 588,531 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares, which Warrants and Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended. 0 788,995 0 788,995 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. K2 HealthVentures Equity Trust LLC /s/ Anup Arora 02/17/2026 Parag Shah /s/ Parag Shah 02/17/2026 Anup Arora /s/ Anup Arora 02/17/2026